Approved Treatment for Relapsed and Refractory Multiple Myeloma

Approved Treatment for Relapsed and Refractory Multiple Myeloma

In Australia around 2,400 people are diagnosed each year with multiple myeloma (MM), and around 20,000 patients are living with MM at any given time.  Unfortunately, more than 1000 patients will die from this form of blood cancer in any given year  and therefore new treatment options such as XPOVIO® are needed.               Antengene Corporation Limited today announced that the Therapeutic Goods Administration (TGA) of the Australian Government Department of Health has registered XPOVIO® (selinexor) for two indications: (1) In […]

Click here to read: eTurboNews | TravelWireNews | TravelNewsOnline

Click here to read the full article.

Approved Treatment for Relapsed and Refractory Multiple Myeloma

 

Source: eTurboNews

Related posts